| ZytoVision–ArchiMed: investment, 202101 acquisition of majority in Zytomed Systems + ZytoVision + 42 Life Sciences by MED II Fund new holding ZytoMax |
2021-01-12 |
| Zymofix–SEVERAL: investment, 202411 financing round €2m led by HTGF |
2024-11-12 |
| Zymofix–High-Tech Gründerfonds: investment, 202411 financing round totalling €2m incl lead investor HTGF |
2024-11-12 |
| Zwisler Laboratorium–Cormica: investment, 202501 acquisition of Zwisler Laboratorium GmbH by Cormica |
2025-01-20 |
| Zukunftsfonds Heilbronn–Ampersand: investment, 202107 acquisition of majority share in PPS from ZFHN and merger with portfolio company GeneWerk |
2021-07-01 |
| Zontal–Bruker: investment, 202305 acquisition $14.8m of Zontal by Bruker |
2023-05-08 |
| Zogenix–UCB: investment, 202201– cash tender offer $1.76b at $26/share plus $135.7m CVR milestones ANNOUNCED |
2022-01-19 |
| Zogenix–HBM: investment, 202201 investment existent at time of $1.76b cash tender offer for Zogenix by UBS |
2022-01-19 |
| Zoetis–Numaferm: peptide technology, 202307– license + collab €na using peptein technology for RnD of veterinary therapeutics |
2023-07-06 |
| Zetta Genomics–Werfen: investment, 202402 2nd seed financing round expansion totalling £1.8m incl new investor We Venture Capital |
2024-02-08 |
| Zetta Genomics–Univ Cambridge: investment, 202402 2nd seed financing round expansion totalling £1.8m incl existing investor Univ Cambridge |
2024-02-08 |
| Zetta Genomics–Univ Cambridge: investment, 202304 2nd seed financing round totalling £1.9m incl existing + co-investor Cambridge Enterprise |
2023-04-18 |
| Zetta Genomics–Univ Cambridge: investment, 202202 seed financing round totalling £2.5m incl co-investor Cambridge Enterprise |
2022-02-01 |
| Zetta Genomics–SEVERAL: investment, 202402 2nd seed financing round expansion by £1.8m to total of £3.7m |
2024-02-08 |
| Zetta Genomics–SEVERAL: investment, 202304 2nd seed financing round £1.9m with led by Nina Capital |
2023-04-18 |
| Zetta Genomics–SEVERAL: investment, 202202 seed financing round £2.5m with Cambridge Enterprise + Apex Ventures + Nina Capital |
2022-02-01 |
| Zetta Genomics–Apex Ventures: investment, 202402 2nd seed financing round expansion totalling £1.8m incl existing investor Apex Ventures |
2024-02-08 |
| Zetta Genomics–Apex Ventures: investment, 202304 2nd seed financing round totalling £1.9m incl existing + co-investor Apex Ventures |
2023-04-18 |
| Zetta Genomics–Apex Ventures: investment, 202202 seed financing round totalling £2.5m incl co-investor Apex Medical |
2022-02-01 |
| Zellkraftwerk–Canopy Biosciences: investment, 201904 acquisition of Zellkraftwerk GmbH by Canopy Biosciences |
2019-04-29 |
| Zafrens–SEVERAL: investment, 202312 company emerges with $23m in financing led by Prime Movers Lab |
2023-12-11 |
| Zafrens–BY Capital: investment, 202312 company emerges with total of $23m in financing incl co-investor BluYard Capital |
2023-12-11 |
| Yumab–Molcure: AI-based drug discovery, 202410– collab expansion to incl zero-shot AI Ab discovery technology to discover Abs for undrugged targets |
2024-10-08 |
| Yukin Therapeutics–SEVERAL: investment, 201906 financing round €3.3m co-led by Advent France Biotechnology + Medicxi |
2019-06-04 |
| Ymmunobio–Yumab: cancer antibody drug, 202206– collab €na optimisation of CEACAM antibodies by Yumab |
2022-06-16 |
| Ymmunobio–SEVERAL: investment, 202311 seed financing round $1.4m |
2023-11-10 |
| Ygion Biomedical–OTHER: investment, 202405 financing round Series A €15m from Austrian private trust (maybe AVV Investment??) |
2024-05-21 |
| Xund Solutions–Tyrolean Business Angel Network: investment, 202503 financing round pre-Series A totalling €6m incl existing + co-investor tba network |
2025-03-05 |
| Xund Solutions–SEVERAL: investment, 202503 financing round pre-Series A €6m led by Lead Ventures |
2025-03-05 |
| Xund Solutions–SEVERAL: investment, 202209 seed financing round €6m co-led by MMC Ventures + MassMutual Ventures |
2022-09-29 |
| Xund Solutions–Roche: investment, 202209 seed financing round totalling €6m incl co-investor RoX Health |
2022-09-29 |
| Xund Solutions–MMC Ventures: investment, 202209 seed financing round totalling €6m incl co-lead investor MMC Ventures |
2022-09-29 |
| Xund Solutions–MassMutual: investment, 202503 financing round pre-Series A totalling €6m incl existing + co-investor MassMutual Ventures |
2025-03-05 |
| Xund Solutions–MassMutual: investment, 202209 seed financing round totalling €6m incl co-lead investor MassMutual Ventures |
2022-09-29 |
| Xund Solutions–Lead Ventures (HU): investment, 202503 financing round pre-Series A totalling €6m incl new + lead investor Lead Ventures |
2025-03-05 |
| Xund Solutions–Lana Ventures: investment, 202503 financing round pre-Series A totalling €6m incl existing + co-investor Lana Ventures |
2025-03-05 |
| Xund Solutions–Lana Ventures: investment, 202209 seed financing round totalling €6m incl co-investor Lana Ventures |
2022-09-29 |
| Xund Solutions–J&T Ventures (CZ): investment, 202503 financing round pre-Series A totalling €6m incl new + co-investor J&T Ventures |
2025-03-05 |
| XtalPi–Swiss Investment Group: investment, 202009 financing round Series C totalling $318.8m incl existing + co-investor SIG |
2020-09-28 |
| XtalPi–Swiss Investment Group: investment, 201810 financing round Series B-1 extension totalling $46m incl co-investor SIG |
2018-10-24 |
| XtalPi–SEVERAL: investment, 202009 financing round Series C $318.8m co-led by SoftBank Vision Fund 2 + PICC Capital + Morningside |
2020-09-28 |
| XtalPi–SEVERAL: investment, 201810 financing round Series B-1 extension $46m led by China Life Healthcare Fund |
2018-10-24 |
| Xpress Biologics–Polyplus-transfection: investment, 202212 acquisition of Xpress Biologics by Polyplus from ArchiMed et al |
2022-12-07 |
| XPhyto Therapeutics–MC Services: public relations, 202107 service existent MC Services is media contact Europe |
2021-07-20 |
| Xpand Biotechnology–Kuros: investment, 201612 merger acquisition of Xpand Biotechnology BV by Kuros Biosciences AG for up to 2.105m new Kuros shares |
2016-12-19 |
| XO Life–SEVERAL: investment, 202202 financing round more than €2m from SeedLink + MediVentures + Aescuvest et al |
2022-02-16 |
| XGen Venture–SEVERAL: investment, 202212–202412 final closing at €180m of XGen Venture Life Sciences Fund in 12/24 |
2022-12-01 |
| Xell AG–Sartorius: investment, 202107 acquisition €50m plus two revenue-based earn-out components in 2022 to 2025 |
2021-07-29 |
| xbird–Glooko: investment, 202201 acquisition of xbird GmbH by Glooko Inc |
2022-01-31 |
| WMT AG–High-Tech Gründerfonds: investment, 202311 existent HTGF is existing investor in WMT |
2023-11-28 |
| WMT AG–FS Life Science Investment: investment, 202311 investment by FS Investment in WMT as part of current bridge financing |
2023-11-28 |
| Wise (IT)–SEVERAL: investment, 202010 financing round Series C €15m led by CDP Venture Capital SGR |
2020-10-01 |
| Windward Bio–SR One: investment, 202501 financing round Series A totalling $200m incl co-investor SR One |
2025-01-10 |
| Windward Bio–SEVERAL: investment, 202501 financing round Series A $200m led by OrbiMed + Novo Holdings + Blue Owl Healthcare Opportunities |
2025-01-10 |
| Windward Bio–RTW Investments: investment, 202501 financing round Series A totalling $200m incl co-investor RTW Investments |
2025-01-10 |
| Windward Bio–Quan Capital: investment, 202501 financing round Series A totalling $200m incl co-investor Quan Capital |
2025-01-10 |
| Windward Bio–Qiming: investment, 202501 financing round Series A totalling $200m incl co-investor Qiming Venture Partners |
2025-01-10 |
| Windward Bio–OrbiMed: investment, 202501 financing round Series A totalling $200m incl co-lead investor OrbiMed |
2025-01-10 |
| Windward Bio–Omega Funds: investment, 202501 financing round Series A totalling $200m incl co-investor Omega Funds |
2025-01-10 |
| Windward Bio–Novo Group: investment, 202501 financing round Series A totalling $200m incl co-lead investor Novo Holdings |
2025-01-10 |
| Windward Bio–Nan Fung: investment, 202501 financing round Series A totalling $200m incl co-investor Pivotal bioVenture Partners |
2025-01-10 |
| Windward Bio–Kelun Pharmaceutical: TSLP antibody, 202501– license ww excl China + smaller Asian markets to WIN378 from Kelun-Biotech + Harbour Biomed |
2025-01-10 |
| Windward Bio–Blue Owl Capital: investment, 202501 financing round Series A totalling $200m incl co-lead investor Blue Owl Healthcare Opportunities |
2025-01-10 |
| Weriol Group–BRAIN Biotech: investment, 202202 acquisition of 62% of Breatec/Comix for €3.7m upfront + option to acquire remaining shares until 2027Q1 |
2022-02-03 |
| Wellington Partners–UTIMCO: investment, 201907 final closing totalling €210m WPLS-V fund incl new investor UTIMCO |
2019-07-31 |
| Wellington Partners–Univ Texas: investment, 201907 final closing totalling €210m WPLS-V fund incl new investor Univ Texas/Texas A&M Investment Company |
2019-07-31 |
| Wellington Partners–Talanx: investment, 201907 final closing totalling €210m WPLS-V fund incl new investor Talanx |
2019-07-31 |
| Wellington Partners–SEVERAL: investment, 201907 final closing €210m WPLS-V fund incl investors KfW Capital + Talanx + UTIMCO + Univ Texas + EIB |
2019-07-31 |
| Wellington Partners–MC Services: public relations, 202001 service existent by MC Services |
2020-01-08 |
| Wellington Partners–Germany (govt): investment, 201907 final closing totalling €210m WPLS-V fund incl new investor KfW Capital |
2019-07-31 |
| Wellington Partners–EU (govt): investment, 201907 final closing totalling €210m WPLS-V fund incl exisiting investor EIB/EIF |
2019-07-31 |
| Wellington Partners–Consilium: public relations, 201907 service existent by CSC |
2019-07-31 |
| Waters–Plasmion: ionisation technology, 202402– collab co-marketing/promotion of SICRIT ion source with Waters Acquity QDa + Select Series Cycli IMS |
2024-02-21 |
| Waters–Heidrick & Struggles: recruitment services, 202007 supply service placement of Udit Batra as CEO of Waters |
2020-07-01 |
| Waters–Andrew Alliance: automated liquid handling technology, 201902–collab new solutions for LC-MS research |
2019-02-06 |
| Waters–Andrew Alliance: automated liquid handling technology, 201706– collab co-marketing semi-automated sample prep solution |
2017-06-01 |
| WaterSep–Sartorius: investment, 202012 acquisition of WaterSep BioSeparations LLC by Sartorius |
2020-12-09 |
| Voluntis–SEVERAL: investment, 202011 capital increase €5.93m net €5.7m led by Debiopharm Innovation Fund |
2020-11-23 |
| Voluntis–Indigo (Eric Carreel): investment, 202011 capital increase totalling €5.93m incl €1m from existing + co-investor Indigo |
2020-11-23 |
| Voluntis–Debiopharm: investment, 202011 capital increase totalling €5.93m incl €3.92m from new + lead investor Debiopharm Innovation Fund |
2020-11-23 |
| Volumina Medical–SEVERAL: investment, 202403 financing round Series A $21m with existing + new investors |
2024-03-25 |
| Vivoryon–Trophic Communications: public relations, 201910 service existent by Trophic |
2019-10-08 |
| Vivoryon–SEVERAL: investment, 201910– public rights offering €30m–€70m incl Claus Chrisitansen + Den Danske Forskningsfond + T&W Holding + MorphoSys |
2019-10-08 |
| Vivoryon–MorphoSys: investment, 201910– public rights offering totalling €30m–€70m incl €15m but limited to max 19.98% holding from MorphoSys AG |
2019-10-08 |
| Vivoryon–MC Services: public relations, 201910 service existent by MC Services |
2019-10-08 |
| Vividion Therapeutics–SEVERAL: investment, 202102 financing round Series C $135m co-led by new investors Logos Capital + Boxer Capital |
2021-02-24 |
| Vividion Therapeutics–SEVERAL: investment, 201904 financing round Series B $82m led by new investor Nextech Invest |
2019-04-30 |
| Vividion Therapeutics–RA Capital: investment, 202102 financing round Series C totalling $135m incl new + co-investor RA Capital Management |
2021-02-24 |
| Vividion Therapeutics–Nextech: investment, 201904 financing round Series B totalling $82m incl new + lead investor Nextech Invest |
2019-04-30 |
| Vividion Therapeutics–Bayer: investment, 202108– acquisition $1.5b upfront + $500k milestones |
2021-08-05 |
| ViveBiotech–Ampersand: investment, 202412 growth equity investment from Ampersand Capital Partners |
2024-12-04 |
| Vivacta–Novartis: investment, 2012 acquisition by Novartis |
2012-01-01 |
| Visus Therapeutics–Wille Finance: investment, 202103 financing round Series A totalling $36m incl investor Wille AG |
2021-03-09 |
| Visus Therapeutics–SEVERAL: investment, 202108 financing round $20m in preferred stock led by new investor LSP |
2021-08-10 |
| Visus Therapeutics–SEVERAL: investment, 202103 financing round Series A $36m with JJDC + RTW Investments + Wille AG + existing investors |
2021-03-09 |
| Visus Therapeutics–Life Sciences Partners: investment, 202108 financing round totalling $20m in preferred stock incl new + lead investor LSP |
2021-08-10 |
| VisionHealth–SEVERAL: investment, 202302 financing round pre-Series A €3m led by DB Speciality Invest |
2023-02-27 |
| VisionHealth–MC Services: public relations, 202302 service existent MC Services is media contact |
2023-02-27 |
| VisionHealth–Bruchmann Group: investment, 202302 financing round pre-Series A totalling €3m incl new + lead investor DB Speciality Invest |
2023-02-27 |
| Virscidian–Dotmatics: investment, 202409 acquisition of Virscidian by Dotmatics |
2024-09-25 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
Deal: Collaboration or Financing
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
